Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
about
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteratureAdjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk PatientsAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineGerman Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant RadiotherapyNeoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerGenomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyAGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Chemotherapy in early breast cancer: when, how and which one?Breast Cancer 2012 - New AspectsThe impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trialsModelling chemotherapy effects on granulopoiesis.Sentinel Lymph Node Biopsy in Early Breast Cancer.Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits.Epoetin beta for the treatment of chemotherapy-induced anemia: an update.High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.Incidence of acute myeloid leukemia after breast cancer.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Trial watch: Chemotherapy with immunogenic cell death inducersDose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Supportive therapy in medical therapy of head and neck tumors.Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialDefinitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).At cancer diagnosis: a 'window of opportunity' for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancerBreast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewRandomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.Present status of adjuvant chemotherapy for elderly breast cancer patients.Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer.Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients.Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.Chemotherapy regimens in early breast cancer: major controversies and future outlook.Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.
P2860
Q26751249-ED7EE915-FD1A-4791-A7DE-50186AD37302Q26751253-14B78F53-8EE9-4C7A-9BE1-482A465E16D1Q26853619-E96D6E31-C774-4B21-9E21-6D30516C1826Q30313214-9D8D6CD3-6CEE-45C7-BCA3-3AC4A6F3165BQ30317570-F1FE9D8A-6BF7-4884-B126-2CB00AC986D3Q30318240-53AB0097-3A1F-4F12-B9B1-AC1422CB6EE7Q30318610-FBEE7269-82B5-4447-9A0B-05320DBD4117Q30588206-1DC1ED4D-4FB7-4473-9EC0-9870531E0969Q33436678-FBC74007-376D-4D85-A405-08B901010C23Q33659628-1DB3D85B-3019-40EA-AD3E-F722316BC8BEQ33827045-96F6C7F0-0491-4797-999D-2A4F56046674Q34042627-6AF2F960-E724-4BAB-A0BC-206E04F1BB01Q34042640-8C6250EF-EA2D-49EE-AD10-3234AB43B62CQ34209663-44F08433-62A0-4C99-90EC-6DF3C763E4B9Q34352408-FD162164-AC98-47DB-A17D-74CB86A076D8Q34996295-97472899-9360-4B6B-A5BD-93841B833300Q35095599-66A60B0A-DE0E-4DCE-A0CD-1FB63A372152Q35157554-B1CC04E2-A685-4DC7-BCF3-FEBC56D6A709Q35168681-4D9640B0-4B3A-4AFD-8102-2530048BF5E0Q35623087-7BC60443-0189-41FC-B3BB-A75C202D701EQ35640784-539D23A8-7E8B-431F-866C-0D6BE685272CQ35858979-26FAE811-09B9-4BD5-B8E2-2BDA24C66AB0Q36038456-3CB4C21A-0E25-4C54-94FD-1517D13C98C7Q36379148-03BA99E5-C585-4D66-8287-58C4E61DFC3FQ36529853-31FC605C-B87E-4DAB-B6AF-C81E1A574A95Q37021210-75CFF362-7516-43D0-BF23-912B9FFA100BQ37132369-DEBB1501-E9C9-487E-AB43-7E72A2142DFDQ37174738-277CA8A7-CC62-4860-83C0-821B86FBAC8FQ37228051-529CD7D3-BBE1-4B3A-B4BF-EB11AE563996Q37293242-50D843BA-A51E-456C-B175-329B6C390DA7Q37309845-1BE601F7-D139-4EE5-A566-AD8D1E810840Q37507392-32FE622D-629B-498E-8521-D13E1BD7B29CQ37657782-AF6FB83E-BE1E-4245-816D-072C9C1EA845Q37677693-2B988775-D1BF-4548-9C66-B786D2855706Q37722185-237ECE7E-4203-44BF-8612-6082E4854A7BQ38040419-BF2EAD0B-AA9F-4F1C-AC92-53EDFEF52293Q38046516-97CEDEF2-2F05-4B6C-990F-CBA8F8E5F62BQ38056750-8F75985D-61D6-4B75-9F7E-6D6E710544B7Q38081243-77015502-2442-46AB-86BC-7CF7A9FDD9D6Q38115153-AD153029-F7AB-494B-8DB7-F88633B71C83
P2860
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Intense dose-dense sequential ...... lts of an AGO phase III study.
@ast
Intense dose-dense sequential ...... lts of an AGO phase III study.
@en
Intense dose-dense sequential ...... lts of an AGO phase III study.
@nl
type
label
Intense dose-dense sequential ...... lts of an AGO phase III study.
@ast
Intense dose-dense sequential ...... lts of an AGO phase III study.
@en
Intense dose-dense sequential ...... lts of an AGO phase III study.
@nl
prefLabel
Intense dose-dense sequential ...... lts of an AGO phase III study.
@ast
Intense dose-dense sequential ...... lts of an AGO phase III study.
@en
Intense dose-dense sequential ...... lts of an AGO phase III study.
@nl
P2093
P50
P356
P1476
Intense dose-dense sequential ...... lts of an AGO phase III study.
@en
P2093
Andreas du Bois
Axel Hinke
Christian Jackisch
Christian Kurbacher
Christoph Thomssen
Gottfried E Konecny
Hans-Joachim Lueck
Ingo B Runnebaum
Rolf Kreienberg
Ulrike Nitz
P304
P356
10.1200/JCO.2009.24.7643
P407
P577
2010-05-10T00:00:00Z